Referências
Principais artigos
Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-60.Texto completo Resumo
Walewska R, Parry-Jones N, Eyre TA, et al. Guideline for the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2022 Jun;197(5):544-57.Texto completo Resumo
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma [internet publication].Texto completo
Eichhorst B, Robak T, Montserrat E, et al; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Jan;32(1):23-33.Texto completo Resumo
Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021 Dec 1;96(12):1679-705.Texto completo Resumo
Artigos de referência
1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720-48.Texto completo Resumo
2. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-60.Texto completo Resumo
3. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34.Texto completo Resumo
4. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988 Nov;29(3):152-63. Resumo
5. Yao Y, Lin X, Li F, et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022 Jan 11;21(1):4.Texto completo Resumo
6. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019 Nov;94(11):1266-87.Texto completo Resumo
7. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: leukemia - chronic lymphocytic leukemia (CLL). 2024 [internet publication].Texto completo
8. Cancer Research UK. Chronic lymphocytic leukaemia (CLL) statistics. [internet publication].Texto completo
9. Matasar MJ, Ritchie EK, Consedine N, et al. Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites. Leuk Lymphoma. 2006 Nov;47(11):2365-70. Resumo
10. Martínez-Trillos A, Quesada V, Villamor N, et al. Recurrent gene mutations in CLL. Adv Exp Med Biol. 2013;792:87-107. Resumo
11. Slager SL, Lanasa MC, Marti GE, et al. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood. 2021 Apr 15;137(15):2046-56.Texto completo Resumo
12. Brown JR. Clinical rsks for chronic lymphocytic leukemia. J Natl Compr Canc Netw. 2024 Apr;22(3):e247020.Texto completo Resumo
13. Shanafelt TD, Ghia P, Lanasa MC, et al. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010 Mar;24(3):512-20.Texto completo Resumo
14. Lamb MJ, Smith A, Painter D, et al. Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. BMJ Open. 2021 Feb 22;11(2):e041296.Texto completo Resumo
15. Mauro FR, Giammartini E, Gentile M, et al. Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica. 2006 Aug;91(8):1117-20.Texto completo Resumo
16. Slager SL, Kay NE. Familial chronic lymphocytic leukemia: what does it mean to me? Clin Lymphoma Myeloma. 2009;9 Suppl 3(suppl 3):S194-7.Texto completo Resumo
17. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015 Jul 23;126(4):454-62.Texto completo Resumo
18. Goldin LR, Lanasa MC, Slager SL, et al. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol. 2010 Oct;151(2):152-8.Texto completo Resumo
19. Crowther-Swanepoel D, Corre T, Lloyd A, et al. Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. Blood. 2010 Dec 23;116(26):5957-60.Texto completo Resumo
20. Parikh SA, Leis JF, Chaffee KG, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015 Sep 1;121(17):2883-91.Texto completo Resumo
21. Tsang M, Parikh SA. A concise review of autoimmune cytopenias in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2017 Feb;12(1):29-38.Texto completo Resumo
22. Gaidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):329-37.Texto completo Resumo
23. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010 Oct 10;28(29):4473-9.Texto completo Resumo
24. Villamor N, Conde L, Martínez-Trillos A, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013 Apr;27(5):1100-6. Resumo
25. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 28;343(26):1910-6.Texto completo Resumo
26. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1848-54.Texto completo Resumo
27. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1840-7.Texto completo Resumo
28. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26;351(9):893-901.Texto completo Resumo
29. Oscier DG, Gardiner AN, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002 Aug 15;100(4):1177-84.Texto completo Resumo
30. Bulian P, Shanafelt TD, Fegan C, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol. 2014 Mar 20;32(9):897-904.Texto completo Resumo
31. Goldin LR, Pfeiffer RM, Li X, et al. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood. 2004 Sep 15;104(6):1850-4.Texto completo Resumo
32. Walewska R, Parry-Jones N, Eyre TA, et al. Guideline for the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2022 Jun;197(5):544-57.Texto completo Resumo
33. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma [internet publication].Texto completo
34. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010 Mar;23(1):47-59.Texto completo Resumo
35. Autore F, Pasquale R, Innocenti I, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: a comprehensive review. Cancers (Basel). 2021 Nov 19;13(22):5804.Texto completo Resumo
36. Eichhorst B, Robak T, Montserrat E, et al; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Jan;32(1):23-33.Texto completo Resumo
37. Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021 Dec 1;96(12):1679-705.Texto completo Resumo
38. Marionneaux SM, Keohane EM, Lamanna N, et al. Smudge cells in chronic lymphocytic leukemia: pathophysiology, laboratory considerations, and clinical significance. Lab Med. 2021 Sep 1;52(5):426-38.Texto completo Resumo
39. Nowakowski GS, Hoyer JD, Shanafelt TD, et al. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol. 2009 Apr 10;27(11):1844-9.Texto completo Resumo
40. International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016 Jun;17(6):779-90. Resumo
41. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996 Aug;22(5-6):439-47. Resumo
42. Bohn JP, Stolzlechner V, Göbel G, et al. Beta-2-microglobulin maintains overall survival prediction in Binet A stage chronic lymphocytic leukemia patients with compromised kidney function in both treatment eras of chemoimmunotherapy and targeted agents. Cancers (Basel). 2024 Nov 6;16(22):3744.Texto completo Resumo
43. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007 Sep;92(9):1242-5.Texto completo Resumo
44. Rossi D, Gaidano G. The clinical implications of gene mutations in chronic lymphocytic leukaemia. Br J Cancer. 2016 Apr 12;114(8):849-54.Texto completo Resumo
45. American Society of Hematology. Ten things physicians and patients should question. Choosing Wisely, an initiative of the ABIM Foundation. 2021 [internet publication].Texto completo
46. Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016 Jan 21;127(3):303-9.Texto completo Resumo
47. Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015 Oct 15;126(16):1921-4.Texto completo Resumo
48. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208-15.Texto completo Resumo
49. National Comprehensive Cancer Network. Hairy cell leukemia. [internet publication].Texto completo
50. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198-206. Resumo
51. Herling CD, Cymbalista F, Groß-Ophoff-Müller C, et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020 Aug;34(8):2038-50.Texto completo Resumo
52. Langerbeins P, Zhang C, Robrecht S, et al. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood. 2022 Jan 13;139(2):177-87.Texto completo Resumo
53. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. Resumo
54. Kutsch N, Bahlo J, Robrecht S, et al. Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG). Hemasphere. 2020 Feb;4(1):e336.Texto completo Resumo
55. Rotbain EC, Frederiksen H, Hjalgrim H, et al. IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study. Haematologica. 2020 Jun;105(6):1621-9.Texto completo Resumo
56. Eichhorst B, Ghia P, Niemann CU, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024 Sep;35(9):762-8.Texto completo Resumo
57. Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):357-62.Texto completo Resumo
58. Gribben JG. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2020 Mar;188(6):844-51.Texto completo Resumo
59. Medicines and Healthcare products Regulatory Agency. Venetoclax (Venclyxto): updated recommendations on tumour lysis syndrome (TLS). Dec 2021 [internet publication].Texto completo
60. Cheson BD, Heitner Enschede S, Cerri E, et al. Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist. 2017 Nov;22(11):1283-91.Texto completo Resumo
61. Tang CPS, Lip GYH, McCormack T, et al. Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Br J Haematol. 2022 Jan;196(1):70-8.Texto completo Resumo
62. Jain P, Thompson PA, Keating M, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15;123(12):2268-73.Texto completo Resumo
63. Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016 Jul 7;128(1):138-40.Texto completo Resumo
64. Buck B, Chum AP, Patel M, et al. Cardiovascular magnetic resonance imaging in patients with ibrutinib-associated cardiotoxicity. JAMA Oncol. 2023 Apr 1;9(4):552-55. Resumo
65. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 Aug 19;402(10402):641-54.Texto completo Resumo
66. Food and Drug Administration. FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. Nov 2023 [internet publication].Texto completo
67. US Food and Drug Administration. Drug safety communication: FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib). Jun 2022 [internet publication].Texto completo
68. ClinicalTrials.gov. A phase 3 study of duvelisib versus ofatumumab in patients with relapsed or refractory CLL/SLL (DUO). NCT02004522. Jan 2022 [internet publication].Texto completo
69. Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011 May 15;117(10):2127-35.Texto completo Resumo
70. Aue G, Nelson Lozier J, Tian X, et al. Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am J Hematol. 2011 Oct;86(10):835-40.Texto completo Resumo
71. Sabakhtarishvili G, Alshebli M, Bajwa O, et al. Bruton tyrosine kinase degraders: current concepts. Am J Clin Oncol. 2025 Feb 14. Resumo
72. ClinicalTrials.gov. A study of BGB-16673 compared to investigator's choice in participants with chronic lymphocytic leukemia previously exposed to both Bruton tyrosine kinase (BTK) and B-cell leukemia/lymphoma 2 protein (BCL2) inhibitors. Mar 2025 [internet publication].Texto completo
73. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Explorer: chronic lymphocytic leukemia (CLL) SEER relative survival rates by time since diagnosis, 2000-2018. 2022 [internet publication].Texto completo
74. Eichhorst B, Ghia P, Niemann CU, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024 Sep;35(9):762-768.Texto completo Resumo
75. Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020 Jul 30;383(5):460-73. Resumo
76. Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010 Mar;23(1):145-53.Texto completo Resumo
77. Ricci F, Tedeschi A, Morra E, et al. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag. 2009 Feb;5(1):187-207.Texto completo Resumo
78. Fiegl M, Stauder R, Steurer M, et al. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Ann Hematol. 2014 Feb;93(2):267-77. Resumo
79. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2009 Jul 1;115(13):2824-36.Texto completo Resumo
80. Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010 May;149(4):578-86.Texto completo Resumo
81. Fattizzo B, Barcellini W. Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects. Front Oncol. 2020 Jan 10;9:1435.Texto completo Resumo
82. Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008 Feb 1;111(3):1110-6.Texto completo Resumo
83. Shen Y, Coyle L, Kerridge I, et al. Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. EJHaem. 2022 Feb;3(1):129-38.Texto completo Resumo
84. Chatzikonstantinou T, Scarfò L, Karakatsoulis G, et al. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. EClinicalMedicine. 2023 Nov;65:102307.Texto completo Resumo
85. US Food and Drug Administration. FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. Nov 2023 [internet publication].Texto completo
86. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):311-22.Texto completo Resumo
87. Tsimberidou AM, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20;24(15):2343-51.Texto completo Resumo
88. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015 Oct 1;33(28):3199-212.Texto completo Resumo
89. Helman DL Jr, Byrd JC, Ales NC, et al. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest. 2002 Sep;122(3):785-90. Resumo
90. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation [internet publication].Texto completo
O uso deste conteúdo está sujeito ao nosso aviso legal